Patent ID: 8747898
Filing Date: 2014-06-10
Classification: A61K,A61P

Abstract:
1. A sustained release oral formulation comprising: a) a core comprising 75-450 mg of bupropion or a pharmaceutically acceptable salt thereof and 2-10% of a water soluble binder; and b) a single membrane-controlled release coating surrounding the core comprising 1-20% of ethylcellulose based upon the total weight of the dosage form, a pH dependent polymer, and a plasticizer; wherein the sustained release oral formulation is administered once a day and maintains therapeutic plasma levels of bupropion for 12 to 24 hours, provides a Tmax of about 5 to about 8 hours and wherein less than 50% of the bupropion or pharmaceutically acceptable salt thereof is released at 10 hours when measured by the USP 23 dissolution test (type), at 50 rpm, at 37° C. in SGF (pH 1.5).